Abbvie - ABBV Forward P/S Multiple

Brandmark of AbbVie Corp. (ABBV)

Patent cliff risks and debt load at AbbVie Inc. (ABBV) are driving volatility, which the GURU.Markets daily chart reflects through the expected P/S ratio. The 2.80 mark indicates the current valuation level. To stabilize, the holding is developing partnerships with biotech startups, while a smooth CEO transition has helped maintain investor confidence in the business development strategy.

abbvie.com - ABBV Forward P/S Multiple (period 07/04/2022 - 11/15/2026)

AbbVie (ABBV) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart AbbVie Inc.|ABBV - Broker Consensus Forecast
- issuer market value details:
Market Capitalization AbbVie Inc.|ABBV - Full Takeover Company Value
- issuer book value statistics:
Book Value per Share AbbVie|ABBV - Book Capitalization|Market Capitalization to Book Value Ratio abbvie.com|ABBV - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Capital AbbVie Inc.|ABBV - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio AbbVie|ABBV - Company Debts|Debts to Book Capitalization Abbvie|ABBV - Long-Term Debt Volume|Company Short-Term Debts AbbVie|Quick Liquidity Indicator abbvie.com
- financial results and valuation multiples details:
ABBV - Final Profit|Projected Future Earnings AbbVie Inc.|ABBV - Business Payback Period|Future Price to Earnings AbbVie|ABBV - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple AbbVie Inc|ABBV - Operating profit before deduction of amortization|Net earnings per share for the last 12 months AbbVie|ABBV - Net earnings per share for the last four quarters|Quarterly EPS earnings growth abbvie.com|ABBV - Earnings growth in current year|Earnings growth forecast for next year AbbVie Inc.
- total revenue and sales volume data:
ABBV - Company Revenue|Projected Sales Volume Abbvie|ABBV - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple AbbVie Inc.|ABBV - Sales Growth YoY (Last Twelve Months)
Summary company analytics:AbbVie Corp. ABBV
Product sample of abbvie.com

AbbVie Inc. maintains stability through effective portfolio rotation via the launch of new blockbusters and expansion into oncology. The issuer's forward P/S ratio assesses market value relative to expected sales, revealing demand resilience to macroeconomic shocks and the risk of a "value trap." Investors should compare pipeline growth rates with the price action on this chart to determine the optimal entry point for the asset.

Analysis of competing companies

Forward P/S Multiple LLY (Lilly)|Projected Price to Revenue AstraZeneca AB|NVS - Price-to-Projected Revenue Ratio|Merck & Co., Inc. (MRK) - Forward Price-to-Revenue Multiple|Novo Nordisk Group (NVO) - Price-to-Projected Revenue Ratio|Amgen Corp (AMGN) - Forward P/S Multiple|PFE (Pfizer Corp) - Forward P/S Multiple|Market Cap to Projected Revenue SNY (Sanofi Group)|Price-to-Projected Revenue Ratio bms.com (BMY)|GSK (GlaxoSmithKline plc) - Forward Price to Sales|Forward P/S Multiple TAK (Takeda Pharmaceutical Company Limited)|Forward P/S Multiple Teva Pharmaceutical Industries Limited TEVA|drreddys.com - Forward P/S Multiple|Forward Price to Sales VTRS (Viatris Corp)|Roivant Sciences (ROIV) - Price-to-Projected Revenue Ratio|Zai Lab Limited (ZLAB) - Forward P/S Multiple|BHC (Bausch Health) - Forward P/S Multiple|COSM: Forward Price to Sales